These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 2475716)

  • 1. Role of beta adrenoceptors in the hypertrophic response to thyroxine.
    Eliades D; Weiss HR
    J Cardiovasc Pharmacol; 1989 Jul; 14(1):58-65. PubMed ID: 2475716
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Propranolol and thyroxine-induced hypertrophic rabbit hearts: effect on heart size and regional O2 supply/consumption variables.
    Grover GJ; Houghton JM; Weiss HR
    Basic Res Cardiol; 1988; 83(3):268-76. PubMed ID: 2970840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of isoproterenol on coronary blood flow and signal transduction responses in thyroxine-treated rabbit hearts.
    Rodriguez E; Weiss HR; Gonzalez M; Tse J
    J Mol Cell Cardiol; 1993 Aug; 25(8):939-47. PubMed ID: 8263963
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basal muscarinic activity does not impede beta-adrenergic activation in rabbit hearts in controls or thyroxine-induced cardiac hypertrophy.
    Naim KL; Rabindranauth P; Scholz PM; Tse J; Weiss HR
    J Cardiovasc Pharmacol; 1997 Oct; 30(4):405-11. PubMed ID: 9335397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of propranolol, alprenolol, pindolol, and bopindolol on beta 2-adrenoceptor density in human lymphocytes.
    Brodde OE; Wang XL; O'Hara N; Daul A; Schiess W
    J Cardiovasc Pharmacol; 1986; 8 Suppl 6():S70-3. PubMed ID: 2439825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thyroxine-induced cardiac hypertrophy: influence of adrenergic nervous system versus renin-angiotensin system on myocyte remodeling.
    Hu LW; Benvenuti LA; Liberti EA; Carneiro-Ramos MS; Barreto-Chaves ML
    Am J Physiol Regul Integr Comp Physiol; 2003 Dec; 285(6):R1473-80. PubMed ID: 12933361
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative analysis of beta-1 adrenoceptor agonist and antagonist potency and selectivity of cicloprolol, xamoterol and pindolol.
    Hicks PE; Cavero I; Manoury P; Lefevre-Borg F; Langer SZ
    J Pharmacol Exp Ther; 1987 Sep; 242(3):1025-34. PubMed ID: 2888869
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T4-induced cardiac hypertrophy and the perfused and total microvasculature of the heart.
    Weiss HR; Grover GJ
    Can J Physiol Pharmacol; 1987 Sep; 65(9):1848-55. PubMed ID: 2961428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Myocardial metabolic and functional responses to acetylcholine are altered in thyroxine-induced cardiac hypertrophy.
    Weiss HR; Tse J
    Can J Physiol Pharmacol; 1995 Jun; 73(6):729-35. PubMed ID: 7585345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical pharmacology of pindolol.
    Aellig WH
    Am Heart J; 1982 Aug; 104(2 Pt 2):346-56. PubMed ID: 6125094
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrinsic sympathomimetic activity of (-)-pindolol mediated through a (-)-propranolol-resistant site of the beta1-adrenoceptor in human atrium and recombinant receptors.
    Joseph SS; Lynham JA; Molenaar P; Grace AA; Colledge WH; Kaumann AJ
    Naunyn Schmiedebergs Arch Pharmacol; 2003 Dec; 368(6):496-503. PubMed ID: 14608456
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does treatment with beta-adrenergic blocking agents cause a decrease in beta 2-adrenoceptor affinity?
    Blankesteijn WM; Graafsma SJ; Hectors MP; Olde Riekerink EA; Rodrigues de Miranda JF; Thien T
    Eur J Clin Pharmacol; 1992; 42(6):613-8. PubMed ID: 1352497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cardiohemodynamic effects of bopindolol in normotensive conscious dogs. A comparative study with pindolol.
    Ishibashi T; Mitomi A; Tatebe S; Imai S
    Arzneimittelforschung; 1989 Apr; 39(4):454-7. PubMed ID: 2568836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hemodynamic and beta-adrenergic receptor adaptations during long-term beta-adrenoceptor blockade. Studies with acebutolol, atenolol, pindolol, and propranolol in hypertensive patients.
    van den Meiracker AH; Man in't Veld AJ; Boomsma F; Fischberg DJ; Molinoff PB; Schalekamp MA
    Circulation; 1989 Oct; 80(4):903-14. PubMed ID: 2571431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the stereoisomers of beta-adrenoceptor antagonists in conscious A-V blocked dogs.
    Boucher M; Duchêne-Marullaz P; Moundanga JL
    Br J Pharmacol; 1986 Sep; 89(1):119-27. PubMed ID: 2879587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between beta-adrenoceptors and coronary blood flow heterogeneity.
    Upsher ME; Weiss HR
    Life Sci; 1989; 44(17):1173-84. PubMed ID: 2541288
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of propranolol and pindolol on the up-regulation of lymphocytic beta adrenoceptors during acute submaximal physical exercise. A placebo-controlled double-blind study.
    Mäki T; Näveri H; Leinonen H; Sovijärvi A; Lewko B; Härkönen M; Kontula K
    J Cardiovasc Pharmacol; 1990 Apr; 15(4):544-51. PubMed ID: 1691382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An assessment of the partial agonist activity of Ro 31-1118, flusoxolol and pindolol in man.
    McCaffrey PM; Riddell JG; Shanks RG
    Br J Clin Pharmacol; 1987 Nov; 24(5):571-80. PubMed ID: 2893634
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cilazapril prevents cardiac hypertrophy and postischemic myocardial dysfunction in hyperthyroid rats.
    Asahi T; Shimabukuro M; Oshiro Y; Yoshida H; Takasu N
    Thyroid; 2001 Nov; 11(11):1009-15. PubMed ID: 11762709
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac and renovascular effects in the anaesthetized dog of BW A575C: a novel angiotensin converting enzyme inhibitor with beta-adrenoceptor blocking properties.
    Cambridge D; Whiting MV; Allan G
    Br J Pharmacol; 1988 Jan; 93(1):165-75. PubMed ID: 2894874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.